173 related articles for article (PubMed ID: 12751207)
41. Establishment of real-time polymerase chain reaction-based assay for quantitation of Epstein-Barr virus DNA in healthy donors and in patients with EBV associated lymphoma.
Incomserb P; Bhattarakosol P; Kulwichit W; Chantratita W; Hansasuta P
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S280-6. PubMed ID: 16623042
[TBL] [Abstract][Full Text] [Related]
42. Polymerase chain reaction study of Epstein-Barr virus in high risk group of nasopharyngeal carcinoma: a preliminary report.
Luxamechanporn T; Neimhom S; Kunachak S; Kulapaditharom B
J Med Assoc Thai; 1999 Jun; 82(6):593-7. PubMed ID: 10443082
[TBL] [Abstract][Full Text] [Related]
43. HLA Class II alleles and the presence of circulating Epstein-Barr virus DNA in Greek patients with nasopharyngeal carcinoma.
Karanikiotis C; Daniilidis M; Karyotis N; Bakogiannis C; Economopoulos T; Murray S; Papamichael D; Samantas E; Nikolaou A; Skoura L; Tselis N; Zamboglou N; Fountzilas G
Strahlenther Onkol; 2008 Jun; 184(6):325-31. PubMed ID: 18535809
[TBL] [Abstract][Full Text] [Related]
44. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type.
Bortolin MT; Pratesi C; Dolcetti R; Bidoli E; Vaccher E; Zanussi S; Tedeschi R; De Paoli P
Cancer Lett; 2006 Feb; 233(2):247-54. PubMed ID: 15907367
[TBL] [Abstract][Full Text] [Related]
45. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer.
Shotelersuk K; Khorprasert C; Sakdikul S; Pornthanakasem W; Voravud N; Mutirangura A
Clin Cancer Res; 2000 Mar; 6(3):1046-51. PubMed ID: 10741733
[TBL] [Abstract][Full Text] [Related]
46. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.
Lo YM; Chan AT; Chan LY; Leung SF; Lam CW; Huang DP; Johnson PJ
Cancer Res; 2000 Dec; 60(24):6878-81. PubMed ID: 11156384
[TBL] [Abstract][Full Text] [Related]
47. Serum/plasma viral DNA: mechanisms and diagnostic applications to nasopharyngeal and cervical carcinoma.
Mutirangura A
Ann N Y Acad Sci; 2001 Sep; 945():59-67. PubMed ID: 11708495
[TBL] [Abstract][Full Text] [Related]
48. [Detecting Epstein-Barr virus in nasopharyngeal carcinoma tissue using in situ polymerase chain reaction].
Xu L; Yang X; Xie L
Zhonghua Zhong Liu Za Zhi; 2000 Jan; 22(1):17-8. PubMed ID: 11776587
[TBL] [Abstract][Full Text] [Related]
49. Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma.
Fafi-Kremer S; Brengel-Pesce K; Barguès G; Bourgeat MJ; Genoulaz O; Seigneurin JM; Morand P
J Clin Virol; 2004 Jun; 30(2):157-64. PubMed ID: 15125872
[TBL] [Abstract][Full Text] [Related]
50. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
Leung SF; Lo YM; Chan AT; To KF; To E; Chan LY; Zee B; Huang DP; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3431-4. PubMed ID: 12960133
[TBL] [Abstract][Full Text] [Related]
51. Clonal versus polyclonal Epstein-Barr virus infection in nasopharyngeal carcinoma cell lines.
Lin CT; Chen W; Hsu MM; Dee AN
Lab Invest; 1997 Jun; 76(6):793-8. PubMed ID: 9194855
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the Epstein-Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms.
Fafi-Kremer S; Morand P; Barranger C; Barguès G; Magro S; Bés J; Bourgeois P; Joannes M; Seigneurin JM
J Mol Diagn; 2008 Jan; 10(1):78-84. PubMed ID: 18165270
[TBL] [Abstract][Full Text] [Related]
53. Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma.
Niemhom S; Kitazawa S; Kitazawa R; Maeda S; Leopairat J
Cancer Detect Prev; 2008; 32(2):127-34. PubMed ID: 18632221
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic value of Epstein-Barr viral serology in nasopharyngeal carcinoma.
Low WK; Leong JL; Goh YH; Fong KW
Otolaryngol Head Neck Surg; 2000 Oct; 123(4):505-7. PubMed ID: 11020195
[TBL] [Abstract][Full Text] [Related]
55. The relationship between secretory leukocyte protease inhibitor expression and Epstein-Barr virus status among patients with nasopharyngeal carcinoma.
Tse KP; Wu CS; Hsueh C; Chang KP; Hao SP; Chang YS; Tsang NM
Anticancer Res; 2012 Apr; 32(4):1299-307. PubMed ID: 22493362
[TBL] [Abstract][Full Text] [Related]
56. [Detection of Epstein-Barr virus DNA in desquamative cell of nasopharyngeal carcinoma by polymerase chain reaction].
Chen W; Chen Y; Ji C
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1994; 29(6):327-9. PubMed ID: 7742020
[TBL] [Abstract][Full Text] [Related]
57. Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States.
O TM; Yu G; Hu K; Li JC
Otolaryngol Head Neck Surg; 2007 Jun; 136(6):992-7. PubMed ID: 17547994
[TBL] [Abstract][Full Text] [Related]
58. Comparison of two laboratory extraction techniques for the detection of Epstein-Barr virus in the saliva of nasopharyngeal carcinoma patients.
Shan J; Pow EH; Tsang PC; Perera RA; Kwong DL
J Investig Clin Dent; 2014 May; 5(2):104-8. PubMed ID: 24574317
[TBL] [Abstract][Full Text] [Related]
59. Detection of Epstein-Barr virus DNA and HHV-6 DNA in tissue biopsies from patients with nasopharyngeal carcinoma by polymerase chain reaction.
Kositanont U; Kondo K; Chongkolwatana C; Metheetrairut C; Puthavathana P; Chantarakul N; Wasi C; Yamanishi K
Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):455-60. PubMed ID: 8160052
[TBL] [Abstract][Full Text] [Related]
60. Comparison of Epstein-Barr virus genotypes and clinicohistopathological features of nasopharyngeal carcinoma between Guilin, China and Fukuoka, Japan.
Zhou Y; Nabeshima K; Koga K; Aoki M; Hayashi H; Hamasaki M; Iwasaki H
Oncol Rep; 2008 Jun; 19(6):1413-20. PubMed ID: 18497945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
